• Consensus Rating: Hold
  • Consensus Price Target: $12.52
  • Forecasted Upside: 61.13 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.77
▼ -0.18 (-2.26%)

This chart shows the closing price for GRFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Grifols Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

Analyst Price Target is $12.52
▲ +61.13% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Grifols in the last 3 months. The average price target is $12.52, with a high forecast of $20.30 and a low forecast of $9.00. The average price target represents a 61.13% upside from the last price of $7.77.

This chart shows the closing price for GRFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Grifols. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2022Morgan StanleyUpgradeEqual Weight ➝ OverweightN/A
11/25/2022Credit Suisse GroupInitiated CoverageNeutral ➝ NeutralLow
11/21/2022BarclaysBoost Target€8.00 ➝ €9.00Low
10/25/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€16.00 ➝ €10.00Low
10/24/2022BarclaysLower TargetUnderweight ➝ Underweight€16.00 ➝ €8.00Low
10/10/2022Morgan StanleyLower Target€20.00 ➝ €13.00Low
9/14/2022JPMorgan Chase & Co.Lower Target€11.50 ➝ €10.30Low
8/2/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€17.00 ➝ €16.00Low
7/25/2022Jefferies Financial GroupInitiated CoverageHoldLow
7/15/2022Berenberg BankBoost TargetBuy ➝ Buy€20.15 ➝ €20.30Low
6/28/2022Berenberg BankLower TargetBuy ➝ Buy€21.40 ➝ €20.60Low
4/8/2022Morgan StanleyInitiated CoverageEqual WeightLow
3/3/2022Berenberg BankLower Target€21.60 ➝ €21.40High
1/4/2022JPMorgan Chase & Co.Lower Target€15.00 ➝ €11.00Low
11/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldMedium
10/19/2021BarclaysDowngradeOverweight ➝ UnderweightMedium
10/6/2021CitigroupUpgradeNeutral ➝ BuyHigh
8/4/2021Credit Suisse GroupReiterated RatingOutperformLow
8/4/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
6/28/2021BarclaysReiterated RatingOverweightLow
6/14/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyMedium
4/27/2021Berenberg BankReiterated RatingBuyMedium
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
3/11/2021HSBCUpgradeHold ➝ BuyHigh
3/10/2021Morgan StanleyReiterated RatingOverweightHigh
3/2/2021Credit Suisse GroupReiterated RatingNeutralLow
3/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/12/2021Berenberg BankReiterated RatingBuyLow
1/22/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupReiterated RatingNeutralLow
1/13/2021Morgan StanleyReiterated RatingOverweightLow
12/9/2020Morgan StanleyReiterated RatingOverweightLow
11/6/2020Morgan StanleyReiterated RatingOverweightLow
10/30/2020Berenberg BankReiterated RatingBuyLow
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
9/30/2020Morgan StanleyReiterated RatingOverweightLow
7/21/2020Berenberg BankReiterated RatingBuyLow
6/23/2020Morgan StanleyReiterated RatingOverweightLow
6/10/2020Berenberg BankReiterated RatingBuyMedium
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
6/1/2020BarclaysReiterated RatingOverweightLow
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
12/12/2019William BlairReiterated RatingOutperformLow
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
10/30/2019Berenberg BankUpgradeBuyLow
10/28/2019SantanderUpgradeHold ➝ BuyLow
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
2/8/2019Berenberg BankDowngradeBuy ➝ HoldHigh
1/2/2019Morgan StanleyLower TargetUnderweight ➝ Underweight$20.00 ➝ $19.00Low
10/30/2018SantanderUpgradeUnderperform ➝ HoldLow
10/11/2018Berenberg BankUpgradeHold ➝ BuyMedium
10/3/2018UBS GroupDowngradeNeutral ➝ SellHigh
10/1/2018Morgan StanleyLower TargetUnderweight ➝ Underweight$22.00 ➝ $20.00Low
6/13/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
6/1/2018BarclaysInitiated CoverageOverweightMedium
3/14/2018HSBCUpgradeReduce ➝ HoldLow
3/1/2018Morgan StanleyLower TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Medium
(Data available from 12/8/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/9/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/9/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/8/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
Grifols logo
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum-from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring-to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $7.77
Low: $7.74
High: $7.91

50 Day Range

MA: $7.01
Low: $5.95
High: $8.47

52 Week Range

Now: $7.77
Low: $5.71
High: $13.34

Volume

570,461 shs

Average Volume

1,071,233 shs

Market Capitalization

$5.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Grifols?

The following Wall Street sell-side analysts have issued stock ratings on Grifols in the last twelve months: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, and StockNews.com.
View the latest analyst ratings for GRFS.

What is the current price target for Grifols?

5 Wall Street analysts have set twelve-month price targets for Grifols in the last year. Their average twelve-month price target is $12.52, suggesting a possible upside of 61.1%. Berenberg Bank has the highest price target set, predicting GRFS will reach $20.30 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $9.00 for Grifols in the next year.
View the latest price targets for GRFS.

What is the current consensus analyst rating for Grifols?

Grifols currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRFS, but not buy more shares or sell existing shares.
View the latest ratings for GRFS.

What other companies compete with Grifols?

How do I contact Grifols' investor relations team?

Grifols' physical mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company's listed phone number is (493) 571-2200 and its investor relations email address is [email protected] The official website for Grifols is www.grifols.com. Learn More about contacing Grifols investor relations.